

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

August 14, 2024

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, August 14, 2024, via webinar, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

Ghassan Al-Sabbagh, MD, Gastroenterologist/Hepatologist, Gastroenterology & Hepatology Consultants
John Anderson, MD, MPH, Associate Professor, Duke Family Medicine, and Community Health
Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center
W. Russell Laundon, PharmD, Pharmacist, Director of Pharmacy Integration, UNC Health Care
Sundar Ramalingam, MD, Oncologist, Duke Cancer Center
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians
Phil Seats, RPh, Retired Pharmacist

MEMBERS ABSENT:

David Konanc, MD, Neurologist, Raleigh Neurology Associates
Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery

PLAN & VENDOR STAFF:

Jenny Vogel, PharmD, Sr. Clinical Pharmacist, State Health Plan
Sam Watts, Executive Director, State Health Plan
Caroline Smart, Sr. Director, Plan Integration, State Health Plan
Justin Wylie, Web Designer, State Health Plan
Renée Jarnigan, RPh, Clinical Advisor, CVS Health
Brian Hermreck, Lead Director, Strategic Accounts, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest Statement

The Chairperson requested that the P&T Committee members review the agenda, which was distributed prior to the meeting, and to disclose any actual or potential conflicts of interest with any item on the agenda. No conflicts of interest were noted.

Old Business

The Chairperson asked the P&T Committee members to review the May 15, 2024 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

Formulary Updates

Ms. Jarnigan began by presenting CVS Caremark's Quarterly Formulary Updates, effective October 1, 2024. This included additions to the formulary, utilization management criteria, product exclusions, and tier movements.

Ms. Jarnigan presented proposed formulary additions, add backs, and line extensions. The three formulary additions are as follows: CAPVAXIVE, MRESVIA, and IXCHIQ INJ. Dr. Robie proposed placing the monkey pox vaccine (JYNNEOS) on the ACA preventative formulary list because of the 8/14/24 World Health Organization Director-General declaring mpox outbreak a public health emergency of international concern. Currently listed on the formulary as Tier 3 (non-ACA). The Plan offered to research the details and respond to the committee with an update shortly. The three add backs are as follows: MEKINIST SOL, TAFINLAR TAB, and VEMLIDY. The five line

extensions are as follows: METHADONE/NACL INJ 5mg/5mL, EXTENCILLINE INJ 1200000; EXTENCILLINE INJ 2400000, XCOPRI TAB 25mg, AUSTEDO XR TAB ER (18mg, 30mg, 36mg, 42mg, 48mg and TITRATION KIT), and VASOSTRICT SOL 40 UNIT.

Ms. Jarnigan and Dr. Vogel identified three new molecular entities that were being removed from CVS's New-to-Market block and would be available as covered products, along with any utilization management policies that went along with the new products. The new molecular entities being added to the formulary are as follows: VELSIPITY, IMDELLTRA, and VANFLYTA.

The Committee also approved proposed utilization management for the new entities including SGM and Specialty QL for VELSIPITY, IMDELLTRA, and VANFLYTA.

There was no opposition from the Committee members, so the formulary additions, add backs, and line extensions with any associated utilization management were approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medically necessary reason to allow coverage of a formulary excluded drug.

Ms. Jarnigan then reviewed that TRUDHESA AER that will be excluded from the formulary starting on the effective date. TRUDHESA AER has therapeutic alternatives that are covered as preferred products on the Plan's custom formulary.

There was no opposition from the Committee members, so the formulary exclusion was approved as presented.

Ms. Jarnigan then identified fourteen branded products which will move from preferred to non-preferred tier status. The fourteen tier changes are as follows: FUZEON INJ, ZOLINZA CAP, LEUKERAN TAB, MATULANE CAP, MYLERAN TAB, TABLOID TAB, VFEND TAB; ORAL SOL, VIBRAMYCIN SUS, RYTHMOL SR CAP, ZIAC TAB, FRAGMIN, ZEMPLAR CAP, ONEXTON GEL, and SALAGEN TAB.

There was no opposition from the Committee members, so the formulary tier changes were approved as presented.

Adjourn

The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on October 16, 2024 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 7:20 P.M. (EST)

Jenny Vogel, Chair